Emerging treatments
Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma(Kmm150). Jung SH et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30019-3. doi: 10.1016/j.bbmt.2018.01.004. [Epub ahead of print]. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma. Comeau JM et al. Am J Health Syst Pharm. 2018…